Geode Capital Management LLC Acquires 6,740 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Geode Capital Management LLC grew its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 0.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,079,509 shares of the company’s stock after buying an additional 6,740 shares during the quarter. Geode Capital Management LLC’s holdings in Voyager Therapeutics were worth $6,316,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Victory Capital Management Inc. raised its stake in shares of Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after acquiring an additional 1,630 shares during the last quarter. Hunter Perkins Capital Management LLC raised its position in Voyager Therapeutics by 3.3% in the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock worth $375,000 after purchasing an additional 2,025 shares during the last quarter. Empowered Funds LLC lifted its holdings in Voyager Therapeutics by 5.4% during the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after buying an additional 2,278 shares in the last quarter. Federated Hermes Inc. lifted its holdings in Voyager Therapeutics by 0.5% during the 2nd quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock worth $4,384,000 after buying an additional 2,638 shares in the last quarter. Finally, ClariVest Asset Management LLC boosted its position in Voyager Therapeutics by 2.7% in the 2nd quarter. ClariVest Asset Management LLC now owns 102,822 shares of the company’s stock valued at $813,000 after buying an additional 2,699 shares during the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on VYGR shares. Leerink Partners started coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective for the company. Wedbush assumed coverage on shares of Voyager Therapeutics in a research note on Friday, November 29th. They set an “outperform” rating and a $11.00 price target for the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Finally, StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $17.43.

Voyager Therapeutics Trading Up 1.2 %

NASDAQ:VYGR opened at $6.04 on Friday. The stock has a market capitalization of $329.94 million, a PE ratio of 8.51 and a beta of 0.90. Voyager Therapeutics, Inc. has a 1-year low of $5.19 and a 1-year high of $11.44. The firm has a fifty day simple moving average of $6.21 and a 200 day simple moving average of $6.90.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. During the same period last year, the firm posted ($0.59) earnings per share. On average, equities analysts predict that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.53% of the stock is owned by company insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.